The alarming frequency of adverse drug events (ADEs) in the United States has prompted legal experts and healthcare professionals to call for comprehensive legislative action. Despite claiming as many as 275,000 American lives annually, this public health challenge fails to receive significant attention, largely because the tragedies unfold on an individual level across various healthcare settings.
ADEs are typically linked with the correct administration and consumption of medications. However, the conventional focus on non-adherence seems misplaced, as significant portions of ADEs occur in line with standard practices. The situation is exacerbated by outdated surveillance systems, leading to underreported incidents, especially affecting women and non-White patients. These groups are particularly at risk due to clinical trials that historically included predominantly White males of European ancestry.
It is estimated that half or more of these medication-related injuries could be prevented through increased education, equitable healthcare access, and technology. Solutions such as pharmacogenomics (PGx) testing present promising avenues by using genetic information to tailor safe and effective drug treatments for individual patients. PGx variations, which occur in over 99% of patients, can prevent significant harms including life-threatening drug-gene interactions.
Despite the potential benefits, obstacles such as inconsistent insurance coverage and lack of federal recognition for pharmacists as healthcare providers limit widespread adoption. Only a few states, covering less than half the nation, have enacted biomarker legislation to mandate insurance coverage for tests that help determine accurate medication prescriptions based on scientific evidence.
Proposed legislative measures like the Right Drug Dose Now Act of 2024 and the Pharmacy and Medically Underserved Areas Enhancement Act aim to address these gaps by updating national action plans, enhancing reporting systems, and incentivizing the adoption of electronic health records that integrate PGx information.
Legal professionals and healthcare stakeholders can learn more and advocate for these advancements by engaging with resources provided by organizations such as the NIH Inter-Society Coordinating Committee for Practitioner Education in Genomics or the American Cancer Society Cancer Action Network. As the urgency for action increases, the unifying goal remains—prioritize legislative support to significantly reduce ADEs and improve patient care across the healthcare spectrum.
For further details, you can read the original piece on MedCity News.